Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 20454B104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
Amendment 1
|
4.0% |
8/14/2026
Event 6/30/2026
|
|
| Vivo Opportunity Fund Holdings, L.P. | 4.0% | ||
| Vivo Opportunity, LLC | 4.0% | ||
| Vivo Opportunity Cayman Fund, L.P. | 0.3% | ||
| Vivo Opportunity Cayman, LLC | 0.3% | ||
| State Street Corp 13G | 5.5% |
8/7/2026
Event 6/30/2026
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
4.3% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 2.3% | ||
| BVF I GP LLC | 2.3% | ||
| Biotechnology Value Fund II LP | 1.7% | ||
| BVF II GP LLC | 1.7% | ||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||
| BVF Partners OS Ltd. | 0.3% | ||
| BVF GP Holdings LLC | 4.0% | ||
| BVF Partners L P/IL | 4.3% | ||
| BVF Inc/IL | 4.3% | ||
| Lampert Mark N | 4.3% | ||
|
Blackstone Holdings II L.P.
13G/A
Amendment 1
|
3.4% |
2/13/2026
Event 12/31/2025
|
|
| Blackstone Annex Master Fund L.P. | 1.4% | ||
| Spruce Street Aggregator L.P. | 2.1% | ||
| Blackstone Alternative Asset Management Associates LLC | 3.4% | ||
| Blackstone Holdings II L.P. | 3.4% | ||
| Blackstone Holdings I/II GP L.L.C. | 3.4% | ||
| Blackstone Inc. | 3.4% | ||
| Blackstone Group Management L.L.C. | 3.4% | ||
| Stephen A. Schwarzman | 3.4% | ||
| BlackRock, Inc. 13G | 5.2% |
1/21/2026
Event 12/31/2025
|
|
|
Tang Capital Management LLC
13G/A
Amendment 3
|
10.0% |
11/14/2025
Event 9/30/2025
|
|
| Tang Capital Management, LLC | 10.0% | ||
| Kevin Tang | 10.0% | ||
| Tang Capital Partners, LP | 6.0% | ||
| Tang Capital Partners International, LP | 3.2% | ||
| Tang Capital Partners III, Inc | 0.6% | ||
| Tang Capital Partners IV, Inc | 0.2% | ||
|
Tang Capital Management LLC
13G/A
Amendment 3
|
10.0% |
11/14/2025
Event 9/30/2025
|
|
| Tang Capital Management, LLC | 10.0% | ||
| Kevin Tang | 10.0% | ||
| Tang Capital Partners, LP | 6.0% | ||
| Tang Capital Partners International, LP | 3.2% | ||
| Tang Capital Partners III, Inc | 0.6% | ||
| Tang Capital Partners IV, Inc | 0.2% | ||
|
Vivo Opportunity Fund Holdings, L.P.
13G
|
5.1% |
11/14/2025
Event 9/30/2025
|
|
| Vivo Opportunity Fund Holdings, L.P. | 5.1% | ||
| Vivo Opportunity, LLC | 5.1% | ||
| Vivo Opportunity Cayman Fund, L.P. | 0.3% | ||
| Vivo Opportunity Cayman, LLC | 0.3% | ||
|
Biotechnology Value Fund L P
13G
|
5.1% |
10/29/2025
Event 10/22/2025
|
|
| Biotechnology Value Fund L P | 2.7% | ||
| BVF I GP LLC | 2.7% | ||
| Biotechnology Value Fund II LP | 2.0% | ||
| BVF II GP LLC | 2.0% | ||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||
| BVF Partners OS Ltd. | 0.3% | ||
| BVF GP Holdings LLC | 4.7% | ||
| BVF Partners L P/IL | 5.1% | ||
| BVF Inc/IL | 5.1% | ||
| Lampert Mark N | 5.1% | ||
|
Suvretta Capital Management, LLC
13G/A
Amendment 1
|
8.2% |
8/21/2025
Event 8/13/2025
|
|
| Suvretta Capital Management, LLC | 8.2% | ||
| Averill Master Fund, Ltd. | 7.1% | ||
| Aaron Cowen | 8.2% | ||
|
Commander Aggregator, LP
13D/A
Amendment 1
|
4.5% |
8/18/2025
Event 8/14/2025
|
|
| Commander Aggregator, LP | 4.5% | ||
| Enavate Sciences, LP | 4.5% | ||
| Enavate Sciences GP, LLC | 4.5% | ||
| Enavate Sciences Holdings, LLC | 4.5% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 6
|
8.9% |
8/15/2025
Event 8/13/2025
|
|
| Orbimed Advisors LLC | 8.9% | ||
| Orbimed Capital GP V LLC | 8.9% | ||
|
Tang Capital Management LLC
13G/A
Amendment 2
|
9.8% |
8/14/2025
Event 6/30/2025
|
|
| Tang Capital Management, LLC | 9.8% | ||
| Kevin Tang | 9.8% | ||
| Tang Capital Partners, LP | 4.9% | ||
| Tang Capital Partners International, LP | 3.9% | ||
| Tang Capital Partners III, Inc | 0.7% | ||
| Tang Capital Partners IV, Inc | 0.3% | ||
|
Suvretta Capital Management, LLC
13G
|
5.2% |
8/13/2025
Event 6/30/2025
|
|
| Suvretta Capital Management, LLC | 5.2% | ||
| Averill Master Fund, Ltd. | 4.5% | ||
| Aaron Cowen | 5.2% | ||
| MPM BioImpact LLC 13G/A Amendment 1 | 4.1% |
8/12/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 4.6% |
7/16/2025
Event 6/30/2025
|
|
|
Tang Capital Management LLC
13G/A
Amendment 1
|
8.0% |
5/15/2025
Event 3/31/2025
|
|
| Tang Capital Management, LLC | 8.0% | ||
| Kevin Tang | 8.0% | ||
| Tang Capital Partners, LP | 4.0% | ||
| Tang Capital Partners International, LP | 3.1% | ||
| Tang Capital Partners III, Inc | 0.7% | ||
| Tang Capital Partners IV, Inc | 0.2% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 5
|
11.0% |
4/11/2025
Event 4/9/2024
|
|
| Orbimed Advisors LLC | 11.0% | ||
| Orbimed Capital GP V LLC | 11.0% | ||
| OrbiMed Genesis GP LLC | 0% | ||
| Orbimed Capital LLC | 0% | ||
| MPM BioImpact LLC 13G | 6.2% |
2/14/2025
Event 12/31/2024
|
|
|
Adage Capital Partners GP, L.L.C.
13G/A
Amendment 2
|
4.4% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 4.4% | ||
| Adage Capital Partners GP, L.L.C. | 0% | ||
| Robert Atchinson | 4.4% | ||
| Phillip Gross | 4.4% | ||
| BlackRock, Inc. 13G |
5.0%
Checked 5% or less
|
2/4/2025
Event 12/31/2024
|
|
|
Tang Capital Management LLC
13G
|
5.4% |
1/16/2025
Event 1/8/2025
|
|
| Tang Capital Management, LLC | 5.4% | ||
| Kevin Tang | 5.4% | ||
| Tang Capital Partners, LP | 3.4% | ||
| Tang Capital Partners International, LP | 2.0% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 1.10 k | $1.15 k |
| 2026 Q2 | 222 | 166 M | $431 M |
| 2026 Q1 | 211 | 173 M | $919 M |
| 2025 Q4 | 175 | 164 M | $882 M |
| 2025 Q3 | 131 | 153 M | $536 M |
| 2025 Q2 | 108 | 108 M | $282 M |
| 2025 Q1 | 132 | 108 M | $206 M |
| 2024 Q4 | 94 | 101 M | $147 M |
| 2024 Q3 | 81 | 92.2 M | $170 M |
| 2024 Q2 | 85 | 93.1 M | $93.6 M |
| 2024 Q1 | 82 | 94.9 M | $188 M |
| 2023 Q4 | 81 | 86.6 M | $135 M |
| 2023 Q3 | 78 | 89.7 M | $177 M |
| 2023 Q2 | 74 | 90.5 M | $288 M |
| 2023 Q1 | 74 | 81.5 M | $267 M |
| 2022 Q4 | 57 | 80.1 M | $403 M |
| 2022 Q3 | 40 | 67.4 M | $154 M |
| 2022 Q2 | 35 | 61.9 M | $164 M |
| 2022 Q1 | 35 | 62.4 M | $85.4 M |
| 2021 Q4 | 38 | 63.6 M | $202 M |